GlassScriptPhysician profile
Michael S Karasik
NPI 1346344967
$4,459.83
in general payments reported to CMS, 2019-2025
38 companies · $986 in 2025
The $986 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $857 · 2020: $280 · 2021: $74.74 · 2022: $286 · 2023: $983 · 2024: $992 · 2025: $986.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,952 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,952.29 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,061.97 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $671.01 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $430.88 | 2019-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $368.53 | 2019-2025 | Stelara, Tremfya |
| Celgene Corporation | $227.32 | 2021-2024 | Zeposia |
| Gilead Sciences, INC. | $191.78 | 2019-2025 | |
| Ironwood Pharmaceuticals, INC | $182.64 | 2023-2024 | Linzess |
| Intercept Pharmaceuticals, INC. | $178.41 | 2021-2024 | Ocaliva |
| Amgen INC. | $142.98 | 2025 | Uplizna |
| Lilly USA, LLC | $129.99 | 2024-2025 | Omvoh |
| Ardelyx, INC. | $68.54 | 2023-2024 | Ibsrela |
| Aimmune Therapeutics, INC. | $57.87 | 2025 | Zenpep |
| Conmed Corporation | $51.51 | 2023 | Conmed Biliary |
| Genzyme Corporation | $50.36 | 2024 | |
| Boston Scientific Corporation | $49.91 | 2024-2025 | Exalt Model D, Resolution 360 Clip |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merit Medical Systems INC | $48.33 | 2020 | |
| Ucb, INC. | $47.44 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $38.27 | 2023 | Bylvay |
| Vibrant Gastro, INC. | $36.90 | 2024 | Vibrant Starter Kit |
| Shire North American Group INC | $36.52 | 2019 | |
| Madrigal Pharmaceuticals | $33.22 | 2025 | Rezdiffra |
| Orphalan INC | $33.12 | 2024 | Cuvrior |
| Erbe USA INC | $31.20 | 2023 | Erbe |
| Novo Nordisk INC | $29.09 | 2025 | Wegovy |
| Allergan, INC. | $25.95 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.99 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.29 | 2023 | Cyltezo |
| Ferring Pharmaceuticals INC. | $22.90 | 2023 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $22.09 | 2024 | Dupixent |
| Mallinckrodt Hospital Products INC. | $21.96 | 2024 | Terlivaz |
| Braintree Laboratories, INC. | $18.90 | 2024 | Sutab, Suflave |
| Endo Pharmaceuticals INC. | $18.60 | 2019 | |
| Exelixis INC. | $18.52 | 2019 | |
| Nestle Healthcare Nutrition INC. | $18.32 | 2023 | |
| Evoke Pharma, INC. | $17.22 | 2024 | |
| Amag Pharmaceuticals, INC. | $17.04 | 2020 | |
| Romark Laboratories, Lc | $12.26 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Karasik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.